ARGX vs NBIX
Argenx SE and Neurocrine Biosciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | ARGX | NBIX |
|---|---|---|
| Revenue | $4.2B | $2.9B |
| Net income | $1.3B | $478.6M |
| Gross margin | 89.1% | 98.2% |
| Net margin | 31.1% | 16.7% |
| Return on equity | — | 16.4% |
| Diluted EPS | $19.57 | $4.67 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $679.0M | $748.7M |
| Equity | — | $3.3B |
| Net debt / equity | — | — |
| Current ratio | 5.23× | 3.39× |
| Revenue CAGR 5y | 151.5% | 22.3% |
| Profit CAGR 5y | — | 3.3% |
ARGX bills 1.5× the revenue of NBIX, and keeps more of each dollar of revenue as profit (31.1% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | ARGX | NBIX |
|---|---|---|
| FY2025 | $4.2B | $2.9B |
| FY2024 | $2.2B | $2.4B |
| FY2023 | $1.2B | $1.9B |
| FY2022 | $400.7M | $1.5B |
| FY2021 | $497.3M | $1.1B |
| FY2020 | $41.2M | $1.0B |
| FY2019 | $78.5M | $788.1M |
| FY2018 | $21.5M | $451.2M |
| FY2017 | $36.4M | $161.6M |
| FY2016 | $14.7M | $15.0M |
Net income by year
Bottom line
| Fiscal year | ARGX | NBIX |
|---|---|---|
| FY2025 | $1.3B | $478.6M |
| FY2024 | $833.0M | $341.3M |
| FY2023 | $-295.1M | $249.7M |
| FY2022 | $-709.6M | $154.5M |
| FY2021 | $-408.3M | $89.6M |
| FY2020 | $-608.5M | $407.3M |
| FY2019 | $-181.2M | $37.0M |
| FY2018 | $-66.6M | $21.1M |
| FY2017 | $-28.1M | $-142.5M |
| FY2016 | $-21.4M | $-141.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry